Delaware Cancer Action Center

Today, legislation aiming to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans, was voted out of committee and will soon be heard by the full House. This marks the final step before the bill goes to Governor Matt Meyer who, earlier this year, identified biomarker testing access as a priority.

DOVER, DE – The Delaware State Senate has unanimously passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it. Biomarker testing has revolutionized cancer treatment over the last few decades and is increasingly important in the treatment of other conditions, providing

Earlier today, cancer survivors, medical professionals and patient advocates from across Delaware convened in Dover at Legislative Hall as a part of ‘Delaware Advocacy Day.’ The main focus of Advocacy Day, which was hosted by the American Cancer Society Cancer Action Network (ACS CAN) and the Alzheimer’s Association (ALZ), was for volunteers to connect directly with legislators and ask for their support of Senate Bill 120, a bipartisan proposal to improve Delawareans’ access to biomarker testing.

The Delaware General Assembly recently passed Senate Bill 156 with strong bipartisan support, advancing the effort to reform medical debt collection practices in the First State. The bill will now go to Governor Meyer’s desk, providing him with the opportunity to limit the burden of medical debt on Delaware families.